Maura Dickler, M.D., to become Vice President of Late Phase Development at Lilly Oncology
Dr. Dickler is currently the Section Head, Endocrine Therapy Clinical Research Program at
"Dr. Dickler is an internationally recognized oncology leader with drug development expertise spanning a wide range of therapeutic modalities," said Garraway. "Moreover, she is an exceptionally gifted clinician for whom patients are at the center of everything she does. We are thrilled to have Dr. Dickler join us at Lilly."
Dr. Dickler graduated from The
Dr. Dickler's research and clinical accomplishments have led to numerous publications and she has served on various committees including the Breast Committee of
About Lilly Oncology
For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. To learn more about Lilly's commitment to people with cancer, please visit www.LillyOncology.com.
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and newsroom.lilly.com/social-channels. C-LLY
View original content with multimedia:http://www.prnewswire.com/news-releases/maura-dickler-md-to-become-vice-president-of-late-phase-development-at-lilly-oncology-300611499.html